[go: up one dir, main page]

MX2009003563A - Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina. - Google Patents

Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.

Info

Publication number
MX2009003563A
MX2009003563A MX2009003563A MX2009003563A MX2009003563A MX 2009003563 A MX2009003563 A MX 2009003563A MX 2009003563 A MX2009003563 A MX 2009003563A MX 2009003563 A MX2009003563 A MX 2009003563A MX 2009003563 A MX2009003563 A MX 2009003563A
Authority
MX
Mexico
Prior art keywords
containing compounds
protease inhibitors
cysteine protease
fluoro containing
compounds
Prior art date
Application number
MX2009003563A
Other languages
English (en)
Inventor
Jie Liu
John O Link
Craig J Mossman
Soon Hyung Woo
Original Assignee
Virobay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virobay Inc filed Critical Virobay Inc
Publication of MX2009003563A publication Critical patent/MX2009003563A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención es concerniente con compuestos que son inhibidores de proteasas de cisteína, en particular catepsinas B, K, L, F y S y son por consiguiente útiles en el tratamiento de enfermedades moderadas por estas proteasas. La presente invención es concerniente con composiciones farmacéuticas que comprenden estos compuestos y procesos para prepararlos.
MX2009003563A 2006-10-04 2007-10-03 Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina. MX2009003563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84958706P 2006-10-04 2006-10-04
PCT/US2007/080320 WO2008042968A2 (en) 2006-10-04 2007-10-03 Di-fluoro containing compounds as cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
MX2009003563A true MX2009003563A (es) 2009-04-15

Family

ID=39145436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003563A MX2009003563A (es) 2006-10-04 2007-10-03 Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.

Country Status (16)

Country Link
US (1) US7781487B2 (es)
EP (1) EP2079683B1 (es)
JP (1) JP5351030B2 (es)
KR (2) KR101486763B1 (es)
AU (1) AU2007303200B2 (es)
CA (1) CA2664878A1 (es)
DK (1) DK2079683T3 (es)
EA (1) EA022130B1 (es)
ES (1) ES2535603T3 (es)
IL (1) IL197965A (es)
MX (1) MX2009003563A (es)
NZ (1) NZ576105A (es)
PT (1) PT2079683E (es)
TW (1) TWI483720B (es)
WO (1) WO2008042968A2 (es)
ZA (1) ZA200902477B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893112B2 (en) * 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
WO2009123623A1 (en) * 2008-04-01 2009-10-08 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
JP5540004B2 (ja) * 2008-11-13 2014-07-02 ビロベイ，インコーポレイティド システインプロテアーゼ阻害剤としてのハロアルキル含有化合物
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3599287B2 (ja) 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
BR9813197A (pt) 1997-11-05 2000-08-29 Novartis Ag Dipeptìdeo nitrilas
US6685572B2 (en) 1998-07-22 2004-02-03 Ntn Corporation Power transmission mechanism
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
US6506733B1 (en) * 1999-03-15 2003-01-14 Axys Pharmaceuticals, Inc. Compounds and compositions as protease inhibitors
UA76088C2 (en) 1999-03-15 2006-07-17 Axys Pharm Inc N-cyanomethyl amides as cysteine protease inhibitors
ES2199856T3 (es) 1999-09-13 2004-03-01 Boehringer Ingelheim Pharmaceuticals, Inc. Nuevos compuestos heterociclicos, utiles como inhibidores reversibles de cisteina proteasas.
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU7490900A (en) 1999-09-16 2001-04-17 Axys Pharmaceuticals, Inc. Chemical compounds and compositions and their use as cathepsin s inhibitors
ATE387199T1 (de) 2000-01-06 2008-03-15 Merck Frosst Canada Ltd Neue substanzen und verbindungen als protease- inhibitoren
AU2001245764A1 (en) 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
DE60229114D1 (en) 2001-03-02 2008-11-13 Axys Pharm Inc Cathepsincystein-proteasehemmer
SE521652C2 (sv) 2001-03-15 2003-11-25 Canag Diagnostics Ab En skivepitelcellcancerrelaterad fusionsgen och motsvarande fusionsprotein
IL159125A0 (en) 2001-06-01 2004-05-12 Axys Pharm Inc Novel compounds and compositions as cathepsin inhibitors
BR0212535A (pt) 2001-09-14 2004-10-19 Aventis Pharma Inc Compostos e composições como inibidores de catepsina
JP2005504827A (ja) 2001-10-02 2005-02-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆性インヒビターとして有用な化合物
EP1444226A1 (en) * 2001-10-29 2004-08-11 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
EP1446115B1 (en) * 2001-11-13 2008-02-27 Merck Frosst Canada Ltd. Cyanoalkylamino derivatives as protease inhibitors
US20030232863A1 (en) * 2002-03-05 2003-12-18 Bayly Christopher I. Cathepsin cysteine protease inhibitors
CA2484011A1 (en) 2002-05-14 2003-11-27 Axys Pharmaceuticals, Inc. Cysteine protease inhibitors
US7101880B2 (en) * 2002-06-24 2006-09-05 Schering Aktiengesellschaft Peptidic compounds as cysteine protease inhibitors
WO2004033445A1 (en) 2002-10-08 2004-04-22 Merck Frosst Canada & Co. 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
US7326719B2 (en) 2003-03-13 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
WO2004108661A1 (en) 2003-06-04 2004-12-16 Axys Pharmaceuticals Amidino compounds as cysteine protease inhibitors
WO2005021487A1 (en) * 2003-08-27 2005-03-10 Merck Frosst Canada Ltd. Cathepsin inhibitors
WO2005028454A1 (en) 2003-09-18 2005-03-31 Axys Pharmaceuticals, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
BRPI0410979A (pt) 2003-09-18 2006-07-04 Axys Pharm Inc composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
KR20070008517A (ko) * 2003-10-24 2007-01-17 아벤티스 파마슈티칼스 인크. 카텝신 저해물질로서 신규한 케토-옥사디아졸 유도체
WO2005058348A1 (en) 2003-12-11 2005-06-30 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
CA2548600A1 (en) * 2003-12-12 2005-06-23 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
JP2007516295A (ja) 2003-12-23 2007-06-21 アクシス・ファーマシューティカルズ・インコーポレイテッド システインプロテアーゼインヒビターとしてのアミジノ化合物
EP1716158A2 (en) 2004-01-30 2006-11-02 Schering Aktiengesellschaft Silinane compounds as cysteine protease inhibitors
KR20070061877A (ko) 2004-09-17 2007-06-14 바이엘 쉐링 파마 악티엔게젤샤프트 시스테인 프로테아제 억제제를 제조하기 위한 방법 및중간체
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina
US7893112B2 (en) * 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors

Also Published As

Publication number Publication date
EP2079683A2 (en) 2009-07-22
IL197965A (en) 2014-08-31
CA2664878A1 (en) 2008-04-10
TWI483720B (zh) 2015-05-11
ZA200902477B (en) 2010-08-25
AU2007303200A1 (en) 2008-04-10
JP2010505872A (ja) 2010-02-25
PT2079683E (pt) 2015-05-20
US20080214676A1 (en) 2008-09-04
KR101555931B1 (ko) 2015-09-30
WO2008042968A2 (en) 2008-04-10
EA022130B1 (ru) 2015-11-30
KR101486763B1 (ko) 2015-01-28
AU2007303200B2 (en) 2011-10-06
US7781487B2 (en) 2010-08-24
WO2008042968A3 (en) 2008-05-22
JP5351030B2 (ja) 2013-11-27
TW200942232A (en) 2009-10-16
KR20090085612A (ko) 2009-08-07
EP2079683B1 (en) 2015-01-21
EA200900510A1 (ru) 2009-08-28
KR20140112479A (ko) 2014-09-23
ES2535603T3 (es) 2015-05-13
DK2079683T3 (en) 2015-04-27
IL197965A0 (en) 2009-12-24
NZ576105A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
NO20061627L (no) Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
EA201070247A1 (ru) Ингибиторы протеасом
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
NO20075370L (no) Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer
GEP20094679B (en) Dipeptidyl peptidase inhibitors
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
MX2009002740A (es) Inhibidores de renina.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009008925A (es) Compuestos de la formula (i) como inhibidores de proteasa de serina.
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
MX2010002769A (es) Preparacion recombinante de fracciones de bromelaina seleccionadas.
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
WO2005063742A3 (en) Amidino compounds as cysteine protease inhibitors
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
WO2010056877A3 (en) Haloalkyl containing compounds as cysteine protease inhibitors
WO2016027284A3 (en) Piperidine ureas as cathepsin cysteine protease inhibitors
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
MY148355A (en) Crystal form of epothilone b and use in pharmaceutical compositions

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration